{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:28:48Z","timestamp":1794000528780,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.trim.2024.102137","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T16:34:48Z","timestamp":1729528488000},"page":"102137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Outcomes with chimeric antigen receptor T-cell therapy in Rheumatological disorders: A systematic review"],"prefix":"10.1016","volume":"87","author":[{"given":"Fizza","family":"Zulfiqar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moazzam","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Kashif","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zouina","family":"Sarfraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Zainab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Qasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naghmeh","family":"Khavandgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forat","family":"Lutfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiman","family":"Hematti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Umair","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2024.102137_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886442","article-title":"Altered balance of pro-inflammatory immune cells to T regulatory cells differentiates symptomatic from asymptomatic individuals with anti-nuclear antibodies","volume":"13","author":"Gupta","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.trim.2024.102137_bb0010","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1097\/MS9.0000000000000891","article-title":"Chimeric antigen receptor T cell therapy for the treatment of systemic rheumatic diseases: a comprehensive review of recent literature","volume":"85","author":"Bhandari","year":"2023","journal-title":"Ann. Med. Surg."},{"issue":"8","key":"10.1016\/j.trim.2024.102137_bb0015","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"issue":"4","key":"10.1016\/j.trim.2024.102137_bb0020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/ajco.13332","article-title":"The role of immunosuppressive agents in the management of severe and refractory immune-related adverse events","volume":"16","author":"Wang","year":"2020","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.trim.2024.102137_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00005-020-00599-x","article-title":"The application of CAR-T cells in haematological malignancies","volume":"68","author":"Skorka","year":"2020","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.trim.2024.102137_bb0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-med-060512-150254","article-title":"Chimeric antigen receptor therapy for cancer","volume":"65","author":"Barrett","year":"2014","journal-title":"Annu. Rev. Med."},{"issue":"3","key":"10.1016\/j.trim.2024.102137_bb0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/BOR.0000000000000594","article-title":"Pathogenesis and treatment of autoimmune rheumatic diseases","volume":"31","author":"Liu","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.trim.2024.102137_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.899372","article-title":"Preclinical autoimmune disease: a comparison of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and type 1 diabetes","volume":"13","author":"Frazzei","year":"2022","journal-title":"Front. Immunol."},{"issue":"10379","key":"10.1016\/j.trim.2024.102137_bb0045","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"issue":"10416","key":"10.1016\/j.trim.2024.102137_bb0050","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.trim.2024.102137_bb0055","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.trim.2024.102137_bb0060","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","article-title":"Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II: peptide complex modulate the progression of autoimmune diabetes","volume":"96","author":"Zhang","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.trim.2024.102137_bb0065","first-page":"372","article-title":"The Prisma 2020 Statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"Bmj"},{"issue":"24","key":"10.1016\/j.trim.2024.102137_bb0070","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"Jama"},{"issue":"11","key":"10.1016\/j.trim.2024.102137_bb0075","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41409-023-02086-1","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study","volume":"58","author":"Wang","year":"2023","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.trim.2024.102137_bb0080","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.trim.2024.102137_bb0085","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16266","article-title":"Chimeric antigen receptor T-cell therapy's role in antiphospholipid syndrome: a case report","volume":"188","author":"Schmelz","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.trim.2024.102137_bb0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.trim.2024.102137_bb0095","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2024.102137_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1075813","article-title":"The emerging role of regulatory cell-based therapy in autoimmune disease","volume":"13","author":"Ghobadinezhad","year":"2022","journal-title":"Front. Immunol."},{"issue":"19","key":"10.1016\/j.trim.2024.102137_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910828","article-title":"Improving CAR T-cell persistence","volume":"22","author":"Pietrobon","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trim.2024.102137_bb0110","article-title":"Combining chemotherapy with CAR-T cell therapy in treating solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"issue":"10354","key":"10.1016\/j.trim.2024.102137_bb0115","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.trim.2024.102137_bb0120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"1","key":"10.1016\/j.trim.2024.102137_bb0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.trim.2024.102137_bb0130","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.trim.2024.102137_bb0135","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review","volume":"91","author":"Di Stefano","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.trim.2024.102137_bb0140","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s10072-021-05077-6","article-title":"Benefit and danger from immunotherapy in myasthenia gravis","volume":"42","author":"Rodolico","year":"2021","journal-title":"Neurol. Sci."},{"issue":"10424","key":"10.1016\/j.trim.2024.102137_bb0145","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","article-title":"Complement in human disease: approved and up-and-coming therapeutics","volume":"403","author":"West","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.trim.2024.102137_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103104","article-title":"Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders","volume":"21","author":"Man\u00e9-Damas","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.trim.2024.102137_bb0155","series-title":"Cytokine and Reactivity Profiles in SLE Patients Following Anti-CD19 CART Therapy","first-page":"31","author":"Nunez","year":"2023"},{"issue":"2","key":"10.1016\/j.trim.2024.102137_bb0160","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit. Care Med."},{"issue":"21","key":"10.1016\/j.trim.2024.102137_bb0165","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.3390\/jcm10215190","article-title":"Cytokine release syndrome in the immunotherapy of hematological malignancies: The biology behind and possible clinical consequences","volume":"10","author":"Tvedt","year":"2021","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.trim.2024.102137_bb0170","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1177\/08850666231205264","article-title":"A primer on chimeric antigen receptor T-cell therapy-related toxicities for the intensivist","volume":"39","author":"Ong","year":"2023","journal-title":"J. Intensive Care Med."},{"key":"10.1016\/j.trim.2024.102137_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.841117","article-title":"Cytokine release syndrome and associated acute toxicities in pediatric patients undergoing immune effector cell therapy or hematopoietic cell transplantation","volume":"12","author":"Baumeister","year":"2022","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.trim.2024.102137_bb0180","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/13543784.2020.1840549","article-title":"Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease","volume":"29","author":"Zhou","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.trim.2024.102137_bb0185","author":"ClinicalTrials.Gov"}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327424001539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327424001539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T03:54:19Z","timestamp":1732593259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327424001539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":37,"alternative-id":["S0966327424001539"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2024.102137","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes with chimeric antigen receptor T-cell therapy in Rheumatological disorders: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2024.102137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102137"}}